Fabrice Lejeune received his Ph.D. from the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in 2001. He continued his post-doc research at the University of Rochester Medical Center from 2001 to 2005. He is currently a Researcher at the University of Lille, INSERM, Lille, France and the Leader of the Team “Molecular therapeutic approaches of genetic diseases and cancer” at Oncolille. He studies the mechanisms that regulate or deregulate the quality control of protein synthesis with the aim to one day utilize these mechanisms to chemically treat diseases such as cystic fibrosis, muscular dystrophy, and cancer.
Fabrice Lejeune received his Ph.D. from the Institute of Genetics and Molecular and Cellular Biology (IGBMC) in 2001. He continued his post-doc research at the University of Rochester Medical Center from 2001 to 2005. He is currently a Researcher at the University of Lille, INSERM, Lille, France and the Leader of the Team “Molecular therapeutic approaches of genetic diseases and cancer” at Oncolille. He studies the mechanisms that regulate or deregulate the quality control of protein synthesis with the aim to one day utilize these mechanisms to chemically treat diseases such as cystic fibrosis, muscular dystrophy, and cancer.